Peran Vitamin D3 Analog dalam Dermatologi

Penulis

  • Synthia Sari Toha Bagian/SMF Ilmu Kesehatan Kulit dan Kelamin, Fakultas Kedokteran Universitas Sebelas Maret/ RSUD Dr. Moewardi, Surakarta, Indonesia
  • Ahmad Fiqri Bagian/SMF Ilmu Kesehatan Kulit dan Kelamin, Fakultas Kedokteran Universitas Sebelas Maret/ RSUD Dr. Moewardi, Surakarta, Indonesia
  • Nurrachmat Mulianto Bagian/SMF Ilmu Kesehatan Kulit dan Kelamin, Fakultas Kedokteran Universitas Sebelas Maret/ RSUD Dr. Moewardi, Surakarta, Indonesia

DOI:

https://doi.org/10.55175/cdk.v46i8.427

Kata Kunci:

Dermatologi, vitamin D

Abstrak

Kulit memainkan peran penting dalam metabolisme vitamin D3 dan memproduksi hormon aktif, yaitu metabolit vitamin D3 atau 1,25-(OH)2-D3 yang sangat penting untuk pemeliharaan homeostasis kalsium. Penggunaan vitamin D3 analog (VDA) sebagai monoterapi atau terapi kombinasi untuk berbagai penyakit kulit telah banyak dilaporkan dan hasilnya cukup signifikan.

Skin has an important role in vitamin D metabolism, by producing an active hormone - 1,25-(OH)2-D3 - an important factor in calcium homeostasis. The use of vitamin D3 analog (VDA) as monotherapy or in combination for various skin diseases gave encouraging results.

Unduhan

Data unduhan belum tersedia.

Referensi

Gerritsen M, Van de Kerkhof P, Langner A. Long–term safety of topical calcitriol 3 μg g− 1 ointment. Br J Dermatol. 2001;144(s58):17-9

Kim GK. The rationale behind topical vitamin D analogs in the treatment of psoriasis: where does topical calcitriol fit in? J Clin Aesthet Dermatol. 2010;3(8):46

Hanneman K, Scull H, Cooper K, Baron E. Effect of topical vitamin D analogue on in vivo contact sensitization. Arch Dermatol. 2006;142(10):1332

Henderson C, Papworth Smith J, Cunliffe W, Highet A, Shamy H, Czarnetzki B. A double blind, placebo controlled trial of topical 1, 25–dihydroxycholecalciferol in psoriasis. Br J Dermatol. 1989;121(4):493-6.

Norman AW, Bouillon R, Thomasset M. Vitamin D. Gene regulation, structure-function analysis and clinical Application. De Gruyter; 1991.

Van de Kerkhof P, Berth Jones J, Griffiths C, Harrison P, Hönigsmann H, Marks R, et al. Longterm efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol. 2002;146(3):414-22.

Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-81.

Bouillon R, Carmeliet G, Daci E, Segaert S, Verstuyf A. Vitamin D metabolism and action. Osteoporosis Internat. 1998;8(8):13-9.

Kira M, Kobayashi T, Yoshikawa K. Vitamin D and the skin. J Dermatol. 2003;30(6):429-37.

Gudjonsson JE, Elder JT. Psoriasis. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: The McGraw-Hill; 2012. p. 197-231.

Ahn CS, Awadalla F, Huang KE, Yentzer B, Dabade TS, Feldman SR. Patterns of vitamin D analog use for the treatment of psoriasis. J Drugs Dermatol. 2013;12(8):906-10.

Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, et al. The role of vitamin D in cancer prevention. Am J Publ Health. 2006;96(2):252-61.

Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116(8):2062-72

Miller D, Hayes K. Vitamin excess and toxicity. In: Hathcock J, editor. Nutritional toxicology. 1. Netherlands: Elsevier; 1982. p. 81-133

Shahzad A, Shahzad M, Khurshid K. Topical calcipotriol in dermatology. J Pak Assoc Derma. 2006;16(2):104-7

Kavuzlu U. Vitamin D treatment in dermatology. In: Tursen U, editor. Immunomosulatory and immunsuppressive drugs in dermatology. Turkey: Ankara; 2016. p. 287-93.

Wat H, Dytoc M. Off-label uses of topical vitamin D in dermatology: A systematic review. J Cutan Med Surg. 2014;18(2):91-108.

Khullar G, Kanwar A, Singh S, Parsad D. Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB–UVB vs. NB–UVB alone in the treatment of vitiligo: A 24–week prospective right–left comparative clinical trial. J Eur Acad Dermatol Venereol. 2015;29(5):925-32.

Buckhart CN, Katz KA. Other topical medications. In: Lowell A. Goldsmith, Stephen I. Katz, Barbara A. Gilchrest, Amy S. Paller, David J. Leffell, Wollf K, editors. Fitzpatrick's dermatology in general medicine. 2. New York The Mc: Graw Hill Co; 2012. p. 2697-707.

Kerkhof PCvd, Nestlé FO. Psoriasis. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. British: Elsevier; 2012. p. 135-56.

Bleiker T, Bourke J, Mumford R, Hutchinson P. Long-term outcome of severe chronic plaque psoriasis following treatment with high-dose topical calcipotriol. Br J Dermatol. 1998;139:285-6.

Durakovic C, Malabanan A, Holick M. Rationale for use and clinical responsiveness of hexafluoro–1, 25–dihydroxyvitamin D3 for the treatment of plaque psoriasis: A pilot study. Bri J Dermatol. 2001;144(3):500-6

Lebwohl MG. The evolution of vitamin D analogues for the treatment of psoriasis. Arch Dermatol. 1995;131(11):1323-4

Langner A, Verjans H, Stapor V, Mol M, Elzerman J. Treatment of chronic plaque psoriasis by 1-alpha, 25-dihydroxyvitamin D 3 ointment. Berlin: de Gruyter; 1991. p. 430-1

Smith EL, Walworth NC, Holick MF. Effect of 1α, 25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol. 1986;86(6):709-14

Langner A, Ashton P, Kerkhof P, Verjans H. A longterm multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. Br J Dermatol. 1996;135(3):385-9

Lebwohl M, Quijije J, Gilliard J, Rollin T, Watts O. Topical calcitriol is degraded by ultraviolet light. J Invest Dermatol. 2003;121(3):594-5

Jovanović M, Golušin Z. Nonsteroidal topical immunomodulators in allergology and dermatology. Biomed Res Int. 2016;2016.

Leone G, Pacifico A. Profile of clinical efficacy and safety of topical tacalcitol. Acta Biomed. 2005;76(1):13-9

Soleymani T, Hung T, Soung J. The role of vitamin D in psoriasis: A review. Int J Dermatol. 2015;54(4):383-92

Fujiyama T, Ito T, Umayahara T, Tatsuno K, Ikeya S, Funakoshi A, et al. Topical application of vitamin D3 analogue to psoriatic skin preferentially suppresses Th17 cells by both direct and indirect mechanisms. J Dermatol Sci. 2017;86(2):28.

Kao CY, Chen Y, Thai P, Wachi S, Huang F, Kim C, et al. IL-17 markedly up-regulates β-defensin-2 expression in human airway epithelium via JAK and NF-κB signaling pathways. J Immunol. 2004;173(5):3482-91

Kao CY, Kim C, Huang F, R. W. Requirements for two proximal NF-kappaB binding sites and IkappaB-zeta in IL-17A-induced human beta-defensin 2 expression by conducting airway epithelium. J Biol Chem. 2008;283(22):15309-18

Peric M, Koglin S, Dombrowski Y, Groß K, Bradac E. Vitamin D analogs differentially control antimicrobial peptide/‘‘Alarmin" expression in psoriasis. PLoS One. 2009;4(7):6340

Ramsay C, Berth-Jones J, Brundin G, Cunliffe W, Dubertret L, Van de Kerkhof P, et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatol. 1994;189(3):260-4

Diterbitkan

2019-08-01

Cara Mengutip

Toha, S. S., Fiqri, A., & Mulianto, N. (2019). Peran Vitamin D3 Analog dalam Dermatologi. Cermin Dunia Kedokteran, 46(8), 530–533. https://doi.org/10.55175/cdk.v46i8.427

Terbitan

Bagian

Articles